This study constructs HER2-heterogeneous breast cancer models, revealing a key role for HER2lo cells in driving resistance to antibody-drug conjugates (ADCs). It further demonstrates that targeting USP9X and ABCC1 enhances the efficacy of trastuzumab deruxtecan (T-DXd), providing a novel experimental framework for precision therapy in HER2-heterogeneous breast cancer.
Literature Overview
The article titled 'HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies,' published in Cancer Discovery, systematically investigates the functional mechanisms of HER2 heterogeneity during the evolution of resistance to HER2-targeted therapies in breast cancer. The research team established stable models with coexisting HER2hi and HER2lo subpopulations using patient-derived cell lines, integrating single-cell analysis, barcode-based lineage tracing, and CRISPR screening to uncover clonal cooperation and resistance dynamics between the two subpopulations. This work not only validates the clinical association between HER2 heterogeneity and treatment failure but also deeply elucidates its biological basis, identifying actionable molecular targets for overcoming resistance.Background Knowledge
1. Clinical challenge addressed by this study in HER2-positive breast cancer: Although HER2-targeted therapies have significantly improved patient outcomes, up to 40% of HER2+ breast cancers exhibit HER2 heterogeneity (i.e., a subset of tumor cells lacking ERBB2 amplification). These patients respond poorly to antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and are prone to recurrence. Currently, there is a lack of preclinical models that accurately recapitulate human HER2 heterogeneity, hindering mechanistic studies and drug development.
2. Current research bottlenecks in HER2 studies: The conventional view holds that ADCs can eliminate neighboring HER2-negative cells via a 'bystander effect.' However, this study reveals that HER2lo cells are intrinsically resistant to T-DXd, and their proportion correlates positively with IC50, suggesting a resistance mechanism independent of drug diffusion. Moreover, the signaling pathway states, microenvironment interactions, and clonal evolutionary roles of HER2lo cells remain poorly understood.
3. Research rationale: Starting from the clinical observation that patients with HER2 heterogeneity rarely achieve pathological complete response, the authors constructed three stable HER2-heterogeneous models to systematically dissect the genetic, transcriptional, and functional differences between HER2hi and HER2lo subpopulations. Using in vivo lineage tracing, they revealed the dynamic clonal evolution under therapeutic pressure and ultimately identified synthetically lethal targets through CRISPR screening.
Research Methods and Experiments
The authors utilized multiple human HER2-positive breast cancer cell lines (e.g., 21PT, HCC1954), isolating HER2hi and HER2lo subpopulations via fluorescence-activated cell sorting (FACS) to establish long-term, stably co-cultured systems. Using cellular barcoding technology (ClonMapper), both subpopulations were lineage-labeled to track clonal dynamics under T-DXd or TKI treatment, revealing rapid expansion of HER2lo cells under ADC pressure. The clinical relevance was further validated using patient-derived xenograft (PDX) models and patient-derived organoids (PDOs), ensuring translational value.
To investigate resistance mechanisms, the team performed whole-exome sequencing, RNA-seq, CyTOF, and spatial proteomics analyses. They found that although HER2lo cells lack ERBB2 amplification, they exhibit stronger basal-like and mesenchymal signaling features and enhanced communication with stromal cells (e.g., PDPN+ fibroblasts). Furthermore, genome-wide CRISPR-Cas9 screening in co-culture systems identified USP9X and ABCC1 as synthetic lethal targets for T-DXd in HER2lo cells.Key Conclusions and Perspectives
Research Significance and Prospects
This study fundamentally changes the understanding of HER2 heterogeneity: it is not merely a resistance marker but an active participant. The identification of USP9X and ABCC1 as vulnerabilities in HER2lo cells provides direct candidates for developing 'ADC-sensitizing agents.' Future clinical trials should evaluate the efficacy of combining T-DXd with USP9X inhibitors (e.g., G9) or ABCC1 blockers, especially in patients with HER2 heterogeneity.
From a drug development perspective, this work emphasizes the need to incorporate heterogeneity into model design from the outset, avoiding misleading results from monoclonal models. Additionally, spatial multi-omics and lineage tracing should become standard tools in resistance research to capture clonal dynamics. For clinical monitoring, liquid biopsy tracking of ERBB2 copy number changes could provide early warning of resistance evolution.
Conclusion
This study, by establishing clinically relevant HER2-heterogeneous breast cancer models, reveals that HER2lo cells are not merely reservoirs of resistance but actively drive tumor adaptive evolution through clonal cooperation. Their resistance to T-DXd is jointly determined by ABCC1-mediated drug efflux and USP9X-regulated lysosomal escape. Targeting these two nodes effectively sensitizes HER2lo cells and overcomes ADC resistance. These findings provide a new strategy for precision therapy in HER2-heterogeneous breast cancer, emphasizing a shift from 'targeting HER2' to 'targeting the HER2 heterogeneity ecosystem.' From bench to bedside, this work lays a solid foundation for designing more effective combination therapies, developing predictive biomarkers, and optimizing patient stratification, with the potential to significantly improve outcomes for this high-risk population.
